New Zealand · Delayed Price · Currency is NZD Comvita Earnings Call Transcripts
Fiscal Year 2026
-
Strong H1 performance with improved profitability, cash flow, and reduced net debt and inventory. North America drives growth, while China and ANZ remain challenging. Recapitalization and prudent capital management are priorities, with FY26 guidance maintained.
Fiscal Year 2025
-
The meeting focused on progress in financial recovery, recapitalization, and operational reset, with significant cost reductions, debt repayment, and new leadership. Shareholders raised concerns about past governance, but the board committed to transparency, improved engagement, and strategic growth initiatives.
-
FY25 saw revenue decline 4% and a net loss of $104.8 million due to impairments, with positive free cash flow achieved through inventory reduction. The business faces ongoing sector challenges, but a reset is underway, and a Scheme Implementation Agreement with Florenz offers shareholders certainty amid continued volatility.
-
Net loss of $6.5M reported, but cash flow and inventory positions improved significantly. Restructuring, cost savings, and tighter controls are underway, with flat sales and margin stabilization expected through FY 2026. Industry surplus and soft China market remain key challenges.
Fiscal Year 2024
-
The meeting addressed ongoing margin pressures, high inventory, and industry oversupply, with leadership outlining aggressive cost and debt reduction initiatives, product strategy shifts, and a renewed focus on health and wellness. Board changes, voting on director appointments, and climate initiatives were also covered.
-
FY 2024 saw a 12.7% revenue decline and a reported net loss of NZD 77.4 million, driven by market contraction, aggressive price competition, and a significant non-cash impairment. Actions include cost reductions, new product launches, and a focus on cash flow and debt reduction.